Tumor lymphangiogenesis as a potential therapeutic target.
Tumor lymphangiogenesis as a potential therapeutic target.
复制标题
DOI：
10.1155/2012/204946
复制
发表时间：
2012
影响因子：
--
通讯作者：
Francois M
中科院分区：
文献类型：
--
作者：
Duong T;Koopman P;Francois M
转移是癌细胞扩散到远处器官，是癌症患者死亡的主要原因。转移通常由侵入原发肿瘤的淋巴管介导，转移的早期迹象是区域淋巴结（来自原发肿瘤的转移癌细胞定植的第一个淋巴结）中存在癌细胞。了解肿瘤发生和淋巴管生成（与肿瘤生长相关的淋巴管的形成）之间的相互作用将为我们提供调节转移扩散机制的新见解。从长远来看，这些见解将有助于确定新的分子靶点，可用于阻断淋巴管介导的转移并提高患者的生存率。在这里，我们回顾了胚胎淋巴管生成和肿瘤淋巴管生成中重现的分子机制，以期确定旨在抑制肿瘤淋巴管生成并从而抑制转移的治疗的潜在靶标。
Metastasis the spread of cancer cells to distant organs, is the main cause of death for cancer patients. Metastasis is often mediated by lymphatic vessels that invade the primary tumor, and an early sign of metastasis is the presence of cancer cells in the regional lymph node (the first lymph node colonized by metastasizing cancer cells from a primary tumor). Understanding the interplay between tumorigenesis and lymphangiogenesis (the formation of lymphatic vessels associated with tumor growth) will provide us with new insights into mechanisms that modulate metastatic spread. In the long term, these insights will help to define new molecular targets that could be used to block lymphatic vessel-mediated metastasis and increase patient survival. Here, we review the molecular mechanisms of embryonic lymphangiogenesis and those that are recapitulated in tumor lymphangiogenesis, with a view to identifying potential targets for therapies designed to suppress tumor lymphangiogenesis and hence metastasis.